Who
Peter Radovich
Director
Company insider
Files Form 4 as: Director, MBX Biosciences; President and COO, Mirum Pharmaceuticals; Director, Rain Oncology; Senior VP, Operations, Global Blood Therapeutics.
In numbers
- Trades disclosed
- 123
- Buys
- 1
- Sells
- 20
- Bought
- $250K
- Sold
- $9.4M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 17 Aug 2015
- Last trade
- 20 Oct 2026
- Last filed
- 22 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Oct 2026filed 22 Oct 2026 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,200 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | MIRM Mirum PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $326K16,988 at $19.19 | filing |
| 5 Jun 2026filed 8 Jun 2026 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —16,988 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —16,988 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | MIRM Mirum PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $326K16,988 at $19.19 | filing |
| 16 Mar 2026filed 17 Mar 2026 | MIRM Mirum PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.5M16,515 at $91.98 | filing |
| 16 Mar 2026filed 17 Mar 2026 | MIRM Mirum PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.5M16,515 at $91.98 | filing |
| 15 Mar 2026filed 17 Mar 2026 | MIRM Mirum PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —7,220 | filing |
| 15 Mar 2026filed 17 Mar 2026 | MIRM Mirum PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —23,000 | filing |
| 15 Mar 2026filed 17 Mar 2026 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,220 at $0.00 | filing |
| 15 Mar 2026filed 17 Mar 2026 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —23,000 at $0.00 | filing |
| 15 Mar 2026filed 17 Mar 2026 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,220 at $0.00 | filing |
| 15 Mar 2026filed 17 Mar 2026 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —23,000 at $0.00 | filing |
| 15 Mar 2026filed 17 Mar 2026 | MIRM Mirum PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —7,220 | filing |
| 15 Mar 2026filed 17 Mar 2026 | MIRM Mirum PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —23,000 | filing |
| 6 Mar 2026filed 11 Mar 2026 | MIRM Mirum PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $94K5,912 at $15.87 | filing |
| 6 Mar 2026filed 11 Mar 2026 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,912 at $0.00 | filing |
| 6 Mar 2026filed 11 Mar 2026 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,912 at $0.00 | filing |
| 6 Mar 2026filed 11 Mar 2026 | MIRM Mirum PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $94K5,912 at $15.87 | filing |
| 2 Feb 2026filed 3 Feb 2026 | MIRM Mirum PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $272K2,631 at $103.30 | filing |
News
Mirum Pharmaceuticals to report Livmarli trial results Monday (MIRM:NASDAQ)MIRM · seekingalpha.com · 12 Oct 2026
0 headlines in the last 90 days name Peter Radovich; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.